Cardiovascular Diabetology

Article	Citations
Empagliflozin-induced lipidome remodeling in type 2 diabetes: mechanistic insights and translational perspectives	793
Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study	466
Sex differences and sex steroids influence on the presentation and severity of cardiovascular autonomic neuropathy of patients with type 1 diabetes	382
Combined associations of visceral adipose tissue and adherence to a Mediterranean lifestyle with T2D and diabetic microvascular complications among individuals with prediabetes	380
Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study	306
Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction	301
The triglyceride-glucose index is associated with atherosclerosis in patients with symptomatic coronary artery disease, regardless of diabetes mellitus and hyperlipidaemia	299
Comprehensive transcriptomics and metabolomics analyses reveal that hyperhomocysteinemia is a high risk factor for coronary artery disease in a chinese obese population aged 40–65: a prospective cross	295
Associations of combined polygenic risk score and glycemic status with atrial fibrillation, coronary artery disease and ischemic stroke	274
Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study	233
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers	220
In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure	197
Correction to: Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists	188
Correction: Association between triglyceride–glucose index and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study	176
Correction: Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS	176
Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes	174
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes	168
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness an	168
Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes	167
Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization	163
Association between the triglyceride glucose index and in-hospital and 1-year mortality in patients with chronic kidney disease and coronary artery disease in the intensive care unit	157
Risk score for lower-limb amputation and its ability to predict major kidney and cardiovascular events in people with type 1 diabetes	155
Impact of T2DM on right ventricular systolic dysfunction and interventricular interactions in patients with essential hypertension: evaluation using CMR tissue tracking	155
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis	155
Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm	155

Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes	149
The predictive value of atherogenic index of plasma and clonal hematopoiesis of indeterminate potential among patients with STEMI—from a prospective cohort study	142
Type 2 diabetes worsens the outcome of ischemia/reperfusion in female STEMI patients and female db/db mice with HFpEF cardiometabolic phenotype	142
Pericoronary adipose tissue radiomics to improve risk stratification for patients with acute coronary syndrome: a multicenter retrospective cohort study	139
Combined evaluation of arterial stiffness, glycemic control and hypertension for macrovascular complications in type 2 diabetes	139
Impaired lymphangiogenesis in pericoronary adipose tissue correlates with diabetes-aggravated coronary atherosclerosis	138
Dysregulation of hypoxia-inducible factor 1α in the sympathetic nervous system accelerates diabetic cardiomyopathy	137
Healthy longevity-associated protein improves cardiac function in murine models of cardiomyopathy with preserved ejection fraction	135
SREBP1 deficiency aggravates vascular calcification via iASPP-triggered ferroptosis of vascular smooth muscle cells	134
Obesity-induced mesenteric PVAT remodelling is sexually dimorphic, but not driven by ovarian hormones	133
Association between triglyceride–glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation	132
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics	131
Sex‑specific cardiovascular risk in estrogen‑treated androgen‑deprived males: metabolic characterization of glucose, adipose, and lipid pathways	131
Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018	131
The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy	130
Development and validation of a machine learning model for predicting vulnerable carotid plaques using routine blood biomarkers and derived indicators: insights into sex-related risk patterns	130
Surgical treatment on infective endocarditis: impact of diabetes on mortality	128
Epigenetic crossroads in metabolic and cardiovascular health: the role of DNA methylation in type 2 diabetes and cardiovascular diseases	126
The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease	123
The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database	120
The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China	119
BMI-based obesity classification misses children and adolescents with raised cardiometabolic risk due to increased adiposity	118
Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention	118
Multi-modal characterisation of early-stage, subclinical cardiac deterioration in patients with type 2 diabetes	117
Dysregulation of long non-coding RNA gene expression pathways in monocytes of type 2 diabetes patients with cardiovascular disease	116
Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study	116
Nonlinear relationship between atherogenic index of plasma and the risk of prediabetes: a retrospective study based on Chinese adults	109
Association between non-insulin-based insulin resistance indices and cardiovascular events in patients undergoing percutaneous coronary intervention: a retrospective study	107
Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery	106
The association between index-year, average, and variability of the triglyceride-glucose index with health outcomes: more than a decade of follow-up in Tehran lipid and glucose study	106
Long-term dual-trajectories of TyG and LAP and their association with cardiometabolic multimorbidity in midlife: the CARDIA study	105
Association between triglyceride–glucose index and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study	105
Proteinuria and the risk of Incident atrial fibrillation according to glycemic stages: a nationwide population-based cohort study	105
High triglyceride-glucose index and stress hyperglycemia ratio as predictors of adverse cardiac events in patients with coronary chronic total occlusion: a large-scale prospective cohort study	105
Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study	105
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT	103
Impact of red cell distribution width and red cell distribution width/albumin ratio on all-cause mortality in patients with type 2 diabetes and foot ulcers: a retrospective cohort study	103
Longitudinal assessment of coronary plaque regression related to sodium–glucose cotransporter-2 inhibitor using coronary computed tomography angiography	101
Ethnicity should be included as a risk factor for coronary artery calcium score	100
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management	100
Atrial dysfunction: a contrast-free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses	99
Temporal patterns of multi-morbidity in 570157 ischemic heart disease patients: a nationwide cohort study	99
Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study	98
Predicting major adverse cardiac events in diabetes and chronic kidney disease: a machine learning study from the Silesia Diabetes-Heart Project	98
Multi-trajectories of triglyceride-glucose index and lifestyle with Cardiovascular Disease: a cohort study	97
Dual-trajectory of TyG levels and lifestyle scores and their associations with ischemic stroke in a non-diabetic population: a cohort study	95
Normal fasting triglyceride levels and incident type 2 diabetes in the general population	95
Advances in cardiac organoid research: implications for cardiovascular disease treatment	94
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics	93
Correction: Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes	93

Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods	91
The association between the triglyceride–glucose index and vulnerable plaques in patients with type 2 diabetes mellitus: insights from coronary computed tomography angiography	91
Stress hyperglycemia ratio and in-hospital prognosis in non-surgical patients with heart failure and type 2 diabetes	89
Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status: insights from the China Health and Retirement Longitudinal Study (CHARLS)	88
Epicardial adipose tissue volume is associated with impaired left ventricular strain in patients with metabolic syndrome: the mediating role of myocardial energetic efficiency	88
Association between combined atherogenic and frailty index and cardiovascular events: evidence from the CHARLS cohort	86
Impacts of ketogenic diet intervention on cardiometabolic outcomes in obese, dysglycemic mice	85
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal eva	85
Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy	85
Deficiency of neutral cholesterol ester hydrolase 1 (NCEH1) impairs endothelial function in diet-induced diabetic mice	84
Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study	83
Metabolic rewiring through succinate–GPR91 signaling: a fresh perspective on HFpEF energetics	82
Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes	81
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease	81
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes	81
Association of temporal change in body mass index with sudden cardiac arrest in diabetes mellitus	81
Destabilization of cardiac myosin acetylation and sequestration with type 2 diabetes mellitus	80
Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial	79
Modulation of PKCα/ETS1 by klotho restores CYB5R4-dependent mitochondrial function in proximal tubular epithelial cells to attenuate the progression of diabetic kidney disease	79
Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database	78
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach	77
Effects of metabolic syndrome and its components on myocardial microcirculation in obstructive coronary artery disease patients: a CMR perfusion study	77
Triglyceride-glucose index is associated with a higher risk of stroke in a hypertensive population	76
Sex differences in myocardial flow reserve among individuals with type 2 diabetes: insights from the DiaHeart study	75
Preeclampsia as an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5-year prospective study	75
Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide	74
Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial	74
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms	74
The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker	73
Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study	72
Associations of six insulin resistance-related indices with the risk and progression of cardio-renal-metabolic multimorbidity: evidence from the UK biobank	72
The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018	72
Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease	72
Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction: assessment with 3.0 T MRI feature tracking	71
Estimated potassium intake and major adverse cardiovascular events in individuals with type 2 diabetes: a prospective cohort study with trans-ethnic validation	70
Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation	69
Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic card	69
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus	69
Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort	69
Diabetes does not increase in-hospital or short-term mortality in patients undergoing surgical repair for type A aortic dissection: insight from the national readmission database	69
Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CS	68
Distinct compositional alterations in plasma lipoproteins in type 2 diabetes: a cross-sectional study of healthy individuals and diabetics with and without cardiovascular comorbidities	67
Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI	66
Prognostic stratification with composite insulin resistance–inflammation biomarkers in patients with chronic kidney disease and coronary artery disease across glycemic statuses	66
Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study	66
Monocytes perturbation implicated in the association of stress hyperglycemia with postoperative poor prognosis in non-diabetic patients with Stanford type-A acute aortic dissection	66
Phenotypic heterogeneity of type 2 diabetes and risks of complications with a tree-like representation	65
Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis	64
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study	64
The association between triglyceride glucose-waist height ratio index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study	64
The association of triglyceride-glucose and triglyceride-glucose related indices with the risk of heart disease in a national cohort study	64
Combined effect of skeletal muscle mass loss and elevated insulin resistance on heart failure risk in older adults: a community-based longitudinal cohort study	63
Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study	63
Novel lipid indicators and the risk of type 2 diabetes mellitus among Chinese hypertensive patients: findings from the Guangzhou Heart Study	63
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes	63
Longitudinal economic burden of incident complications among metabolic syndrome populations	63
Clonal hematopoiesis of indeterminate potential and type 2 diabetes mellitus among patients with STEMI: from a prospective cohort study combing bidirectional Mendelian randomization	62
Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease	62
Triglyceride glucose-weight-adjusted waist index as a cardiovascular mortality predictor: incremental value beyond the establishment of TyG-related indices	61
Assessment of left atrioventricular coupling and left atrial function impairment in diabetes with and without hypertension using CMR feature tracking	61
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study	61
Association of the triglyceride glucose index with all-cause and cardiovascular mortality in a general population of Iranian adults	61
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease	60
Joint association of the triglyceride–glucose index and stress hyperglycemia ratio with incidence and mortality risks of new-onset atrial fibrillation during sepsis: a retrospective cohort study	59
The predictive value of lesion-specific pericoronary fat attenuation index for major adverse cardiovascular events in patients with type 2 diabetes	58
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management	58
Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists	58
Joint assessment of abdominal obesity and non-traditional lipid parameters for primary prevention of cardiometabolic multimorbidity: insights from the China health and retirement longitudinal study 20	58
Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy	58
Expanded response letter to “Hemodialysis dose and frequency should be considered in the subgroup analysis”	58
Cumulative exposure to the estimated glucose disposal rate and incident stroke in individuals with cardiovascular–kidney–metabolic syndrome stages 0–4: 6-year longitudinal evidence from CHARLS	58
Epicardial adipose tissue volume and arterial stiffness in people living with diabetes: the METAB-CV-PWV study	57
The additional impact of metabolic syndrome on left ventricular deformation and myocardial energetic efficiency impairment in ischemia with nonobstructive coronary arteries patients	57
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study	57
Effects of glycemic traits on left ventricular structure and function: a mendelian randomization study	57
Ancestry-specific genetics of amino acids and microbiota-related metabolites reveal causal effects on cardiometabolic disease in Chinese populations	57
Comprehensive CMR evaluation including 4D flow-derived E/A vorticity ratio in overweight adults with and without type 2 diabetes mellitus	56
The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells	56
Predicting gestational diabetes mellitus risk at 11–13 weeks’ gestation: the role of extrachromosomal circular DNA	56
Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study	56

Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials	56
Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular disease	55
Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes	55
Body-weight variability and risk of cardiovascular outcomes in patients with type 1 diabetes: a retrospective observational analysis of data from the DCCT/EDIC population	55
Effects of diabetes mellitus on left ventricular function and deformation in patients with restrictive cardiomyopathies: a 3.0T CMR feature tracking study	55
Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial	55
One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis	55
Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation	54
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study	54
The novel triglyceride‒glucose-weighted adjusted waist index as a supplementary diagnostic tool for heart failure: evidence of improved reclassification beyond traditional TyG-related indices from a c	54
Nanocarrier SIroliMus-coated balloon-based percutaneous coronary intervention (PCI) versus drug-eluting stent (DES)-onLy PCI in patients with diabetes mellitus	54
Heart rate variability tests for diagnosing cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus in advanced stages of kidney disease	54
Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study	54
Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study	53
Sex-specific cardiometabolic multimorbidity, metabolic syndrome and left ventricular function in heart failure with preserved ejection fraction in the UK Biobank	53
Pathways from insulin resistance to incident cardiovascular disease: a Bayesian network analysis	53
Metabotype identification via fasting and postprandial metabolomics and its association with type 2 diabetes incidence	53
The neutrophil–lymphocyte ratio as a risk factor for all-cause and cardiovascular mortality among individuals with diabetes: evidence from the NHANES 2003–2016	52
Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries	52
Mitochondrial network remodeling of the diabetic heart: implications to ischemia related cardiac dysfunction	52
ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III	52
Adipsin improves diabetic hindlimb ischemia through SERPINE1 dependent angiogenesis	52
GPR30-driven fatty acid oxidation targeted by ginsenoside Rd maintains mitochondrial redox homeostasis to restore vascular barrier in diabetic retinopathy	52
Independent association of thigh muscle fat density with vascular events in Korean adults	51
Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes	51
Associations of different insulin resistance-related indices with the incidence and progression trajectory of cardiometabolic multimorbidity: a prospective cohort study from UK biobank	50
Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospectiv	50
Cardiovascular risk of metabolically healthy obesity in two european populations: Prevention potential from a metabolomic study	50
Triglyceride glucose index predicts long-term mortality and major adverse cardiovascular events in patients with type 2 diabetes	50
Association between the triglyceride–glucose index and severity of coronary artery disease	49
Triglyceride-glucose-related indices and risk of cardiovascular disease and mortality in individuals with cardiovascular–kidney–metabolic (CKM) syndrome stages 0–3: a prospective cohort study of 282,9	49
Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials	48
Associations between glycated hemoglobin and the risks of incident cardiovascular diseases in patients with gout	48
Ion channel Piezo1 activation aggravates the endothelial dysfunction under a high glucose environment	48
Predicting 28-day all-cause mortality in patients admitted to intensive care units with pre-existing chronic heart failure using the stress hyperglycemia ratio: a machine learning-driven retrospective	48
Endothelial microRNAs in INOCA patients with diabetes mellitus	48
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study	47
Correction to: Association between the triglyceride-glucose index and the risk of mortality among patients with chronic heart failure: results from a retrospective cohort study in China	47
ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling	47
Correction: Nut consumption is associated with a shift of the NMR lipoprotein subfraction profile to a less atherogenic pattern among older individuals at high CVD risk	47
Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: “INSIST” study	46
Daily low dose aspirin halves incident type 2 diabetes in elderly subjects with prediabetes: a five-year longitudinal cohort study in a real-word population	46
Multi-dimensional characterization of prediabetes in the Project Baseline Health Study	46
Joint association of urinary albumin-to-creatinine ratio within normal range and triglyceride-glucose index with incident cardiovascular disease: a prospective cohort study	46
Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study	45
Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study	45
Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry	44
Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study	44
Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes	44
Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study	44
Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study	44
The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease	44
Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial	44
Relationship between TyG index and the degree of coronary artery lesions in patients with H-type hypertension	44
Associations between the C-reactive protein-triglyceride glucose index and the incidence and progression trajectory of cardiometabolic multimorbidity: a multi-state model study	44
Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study	44
Impact of mental disorders on the risk of atrial fibrillation in patients with diabetes mellitus: a nationwide population-based study	43
The triglyceride-glucose index: a novel predictor of stroke and all-cause mortality in liver transplantation recipients	43
Arterial stiffness in patients with type 1 diabetes and its comparison to cardiovascular risk evaluation tools	43
Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care	43
Joint associations of anthropometric indices and C-reactive protein-triglyceride-glucose index with incident hypertension: a stratified analysis by blood pressure level from the CHARLS, 2011–2020	43
The right ventricular dysfunction and ventricular interdependence in patients with T2DM and aortic regurgitation: an assessment using CMR feature tracking	43
Single-cell insights: pioneering an integrated atlas of chromatin accessibility and transcriptomic landscapes in diabetic cardiomyopathy	42
Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population	42
Insulin resistance quantified by estimated glucose disposal rate predicts cardiovascular disease incidence: a nationwide prospective cohort study	42
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes	42
Association between the stress hyperglycemia ratio and severity of coronary artery disease under different glucose metabolic states	42
The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode	41
Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study	41
Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based	41
MiRNA-132/212 encapsulated by adipose tissue-derived exosomes worsen atherosclerosis progression	41
Associations of estimated glucose disposal rate with frailty progression: results from two prospective cohorts	41
The association between TyG index and cardiovascular mortality is modified by antidiabetic or lipid-lowering agent: a prospective cohort study	41
Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease	41
Evaluative performance of TyG-ABSI versus traditional indices in relation to cardiovascular disease and mortality: evidence from the U.S. NHANES	40
Association between triglyceride glucose index and arterial stiffness and coronary artery calcification: a systematic review and exposure-effect meta-analysis	40
Lifestyle factors and their relative contributions to longitudinal progression of cardio-renal-metabolic multimorbidity: a prospective cohort study	40
Bone marrow mesenchymal stem cell-derived extracellular vesicles alleviate diabetes-exacerbated atherosclerosis via AMPK/mTOR pathway-mediated autophagy-related macrophage polarization	40
Association of cumulative cholesterol-HDL-glucose index with blood pressure changes and risk of new-onset hypertension in middle-aged and older adults: a cohort study	40
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes	40
GULP1 protects against diabetic cardiomyopathy through IKIP/NF-κB-dependent improvement of mitochondrial function	40
Contributions of elevated CRP, hyperglycaemia, and type 2 diabetes to cardiovascular risk in the general population: observational and Mendelian randomization studies	40
Altered RBC deformability in diabetes: clinical characteristics and RBC pathophysiology	39
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention	39
Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study	39
Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident cardiovascular disease in middle-aged and older Chinese adults: a nation	39
Cardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia	39
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial	39
Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation	39
Elevated triglyceride-glucose index and risk of thymoma-associated myasthenia gravis: a prospective analysis from the UK Biobank	39
Low-frequency variants in genes involved in glutamic acid metabolism and γ-glutamyl cycle and risk of coronary artery disease in type 2 diabetes	39
Associations of genetic markers of diabetes mellitus with carotid atherosclerosis: a community-based case–control study	39
Probing erythrocytes as sensitive and reliable sensors of metabolic disturbances in the crosstalk between childhood obesity and insulin resistance: findings from an observational study, in vivo challe	38
Obesity cardiomyopathy could contribute to sudden cardiac death: a Japanese epidemiological morphological study	38
Association of insulin use with LV remodeling and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: assessed by cardiac MRI	38